Mary W. Redman

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa — South Africa

Medicine · Health Sciences

44h-index7.2kcitations435works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(180), Cancer Genomics and Diagnostics(87), Cancer Immunotherapy and Biomarkers(68), Lung Cancer Research Studies(60), Lung Cancer Diagnosis and Treatment(41)

Publications434 total

Early Stopping of Clinical Trials Evaluating Targeted Therapies
2025
Supplemental Figure 4 from Elevated <i>EVL</i> Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
2025Open Access
Supplemental Table 6 from Elevated <i>EVL</i> Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
2025Open Access
Supplemental Table 3 from Elevated <i>EVL</i> Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
2025Open Access
Supplemental Table 1 from Elevated <i>EVL</i> Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
2025Open Access
Supplemental Figure 2 from Elevated <i>EVL</i> Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
2025Open Access
Supplemental Table 2 from Elevated <i>EVL</i> Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
2025Open Access
Supplemental Table 5 from Elevated <i>EVL</i> Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
2025Open Access
Supplemental Table 4 from Elevated <i>EVL</i> Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
2025Open Access
Supplemental Figure 3 from Elevated <i>EVL</i> Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
2025Open Access
Supplemental Table 7 from Elevated <i>EVL</i> Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
2025Open Access
Supplemental Figure 1 from Elevated <i>EVL</i> Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas
2025Open Access
Supplementary Table S1 from Phase II Study of Docetaxel and Trametinib in Patients with <i>KRAS</i> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
2025Open Access
Supplementary Figure S1 from Phase II Study of Docetaxel and Trametinib in Patients with <i>KRAS</i> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
2025Open Access
Supplementary Table S3 from Phase II Study of Docetaxel and Trametinib in Patients with <i>KRAS</i> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
2025Open Access
Supplementary Table S2 from Phase II Study of Docetaxel and Trametinib in Patients with <i>KRAS</i> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
2025Open Access
OA09.01 Machine Learning Assessment of Pathologic Response in Lung Resections After Neoadjuvant Therapy - IASLC MPR Project
Journal of Thoracic Oncology·2025
Data from Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non–Small Cell Lung Cancer: A Lung-MAP Study
2025Open Access
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial
European Urology·2025· 7 cited
PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.
Journal of Clinical Oncology·2025· 8 cited
page 1 of 22Next →

Frequent Co-authors

David R. Gandara(28), Karen Kelly(18), Roy S. Herbst(15), Philip C. Mack(13), Vassiliki A. Papadimitrakopoulou(10), Fred R. Hirsch(10), Primo N. Lara(8), Suresh S. Ramalingam(8), Katherine Minichiello(8), Jieling Miao(8), James Moon(7), Lawrence H. Schwartz(6), Jeffrey D. Bradley(6), Kari Chansky(5), Kelsey K. Baker(5), John J. Crowley(5), Thomas E. Stinchcombe(5), Anne S. Tsao(4), Everett E. Vokes(4), Natasha B. Leighl(4)